REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (REDEFINE 3)
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
Sponsor: Novo Nordisk A/S
A PHASE3 clinical study on Cardiovascular Disease, this trial is ongoing. The trial is conducted by Novo Nordisk A/S and has accumulated 29 data snapshots since 2023. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
29 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Jan 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 24 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Feb 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .